Lyell Immunopharma LYEL
NASDAQ LYEL
$9.38 -0.03 (-0.32%)
At close: Oct 22, 2026 · 4:00 PM EDT

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2020 - 2021)

Updated

Lyell Immunopharma (LYEL) reported Preferred Stock Liabilities of $1.01 billion for Q1 2021, unchanged from the prior quarter.

Analysis

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Dating back to Q2 2020, Lyell Immunopharma's Preferred Stock Liabilities record includes 4 quarters.

  • By year, Preferred Stock Liabilities came in at $519.16 million in FY2019.
  • Per Business Quant data, the three quarters before Q1 2021 came in at $1.01 billion (Q4 2020), $1.01 billion (Q3 2020) and $1.01 billion (Q2 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Lyell Immunopharma 219.46 Mn -805.51 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 1.01 Bn
Dec 31, 2020 1.01 Bn
Sep 30, 2020 1.01 Bn
Jun 30, 2020 1.01 Bn
API Access

Lyell Immunopharma Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=LYEL&period=max&api_key=YOUR_API_KEY